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Background: TAVR has emerged as an attractive alternative for treatment of severe aortic
stenosis in high risk surgical patients. Despite several large multicenter registries, only one
randomized trial (PARTNER) has been published.
Objective:We aimed to compare the outcomes obtained using multicenter registries and the
PARTNER trial.
Methods: StandardMEDLINE search strategywasused tofindmulticenter registries, reporting
clinicaloutcomes followingTAVR.Meta-analytic techniqueswereutilized tocalculatepooled
outcomes across multicenter registries and compare them to outcomes in PARTNER trial.
Results: Pooled 30-day mortality rate from the registries was 9.2%, which was significantly
higher than that in the PARTNER trial (3.8%). Medium-term mortality rates were similar
between the PARTNER trial and the multicenter registries. Pooled 30-day and 1-year stroke
rates in multicenter registries were 2.6% and 3.8%, respectively. On the other hand, the
corresponding rates in PARTNER trial were 5.2% and 7.6%, respectively. In the registry-
related cohorts, pooled 30-day and 1-year mortality rates were 6.8% and 20.8% in the
transfemoral group and 12.2% and 32.2% in the transapical group. In the PARTNER trial, the
pooled incidence of 30-day and 1-year mortality rates were 3.9% and 26.2% in the trans-
femoral group and 3.8% and 29.0% in the transapical group.
Conclusions: Short-term results in PARTNER were better than those reported in the regis-
tries, which may be due to better patient selection and aggressive bailout techniques.
Similarity of medium-term outcomes between registries and PARTNER highlights that
patient selection for TAVR is critical due to considerable risk of mortality in the first year
even after the successful procedure.
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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1 4011. IntroductionDegenerative aortic stenosis (AS) is the one of the most
commonly acquired valvular heart disease in aging adults.1 In
patients with symptomatic AS, surgical aortic valve replace-
ment (SAVR) has been the treatment of choice for over 4
decades. The overall mortality for isolated AVR ranges from
2.5e4.0%.2e4 However, it is estimated that roughly 30e60% of
the patients with symptomatic AS are deemed “high-risk” for
conventional AVR4e6 and may be denied open-heart surgery.
Rapid advancements in transcatheter technology led to the
innovation of transcatheter aortic valve replacement (TAVR).
Recently, there has been a rapid surge in the utilization of
TAVR to treat high-risk patients with severe symptomatic AS.
The rapid worldwide dissemination of this new technique
carries the hazard that patients who are candidates for con-
ventional SAVR would be treated percutaneously. The “off-
label” use of TAVR has been estimated to be as high as 67% in
some centers.7 Currently, there are two device types available
for TAVR: balloon expandable Edwards valve (Edwards Life-
sciences, USA) and the self-expanding CoreValve system
(Medtronic, Inc, USA).
The multicenter randomized controlled Placement of Aortic
Transcatheter Valves (PARTNER) trial has demonstrated simi-
larity of SAVR and TAVR with respect to mortality, reduction
in symptoms and improvement in valve hemodynamics, up to
two years of follow up.8e11 While robust clinical evidence
emanating from rigorously conducted randomized trials is a
cornerstone of premarket conformity assessment process, it is
of paramount importance to recognize the shortcomings of
these premarket clinical assessments. The follow-up is still
limited, the study populations are pre-selected. Further, the
initial sites for the clinical trial typically consisted of largeTable 1 e Characteristics of included registries and clinical tria
Author/publication year Study n Period of
study
Num
ce
Registry data
Piazza/2008 European
registry
646 4/2007e4/2008
Rodes-Cabau/2010 Canadian 339 1/2005e6/2009
Thomas/2010 SOURCE 1038 11/2007e1/2009
Zahn/2010 German 697 1/2009e12/2009
Eltchaninoff/2010 FRANCE 244 2/2009e7/2009
Bosmans/2010 Belgian 328 Till 4/2010
Tamburino/2011 Italian 663 6/2007e12/2009
Lefevre/2011 PARTNER-EU 130 4/2007e1/2008
Moat/2011 UK-TAVI 870 12/2007e12/2009
Meredith/2011 Australia
New Zealand
118 8/2008e7/2010
Gilard/2012 FRANCE 2 3195 1/2010e10/2011
Randomized control trial data
Leon/2010 PARTNER
Cohort B
179 5/2007e3/2009
Smith/2011 PARTNER
Cohort A
348 5/2007e8/2009
TA: transapical; TF: transfemoral.academic centers with tremendous oversights. As formal
post-marketing surveillance programs will be instituted, out-
comes data from multicenter and/or national registries will
become increasingly important. This review summarizes and
compares the data from US randomized trial to these multi
center registries outside of US.2. Multicenter registries and randomized
control trials for TAVR
TAVR was introduced in clinical practice in 2002 and commer-
cial use with the Edwards valve and CoreValve began outside
the US in 2007. The earliest experience with the Edwards valve
was reported in the Canadian registry comprising experience
between 2005 and 2009 and the SAPIEN Aortic Bioprosthesis Eu-
ropean Outcome (SOURCE) registry comprising experience be-
tween 2007 and 2009.12,13 The earliest experience with the
CoreValve was reported in the multicenter expanded evalua-
tion registry comprising experience between 2007 and 2008.14
Till date, several multicenter registries of TAVR have been
assembled and described.12e22 These registries provide the re-
sults after commercialization of the available devices and
reflect real-world experience, with the exception of US.
Table 1 describes the characteristics of 11 large representa-
tive registries that have been described in the literature along
with the two cohorts of the PARTNER trial. Of these 11 registries,
3 have exclusively described CoreValve experience,14,17,22 3
have exclusively described Edwards valve experience12,13,16 and
the rest have reported combined experiences with both
valves.15,18e22 Transfemoral approach seemed to be the favored
approach in most registries and was adopted in 46.9e95.8% of
all reported cases.ls with transcatheter aortic valve replacement.
ber of
nters
Edwards
valve n
Core
valve n
TF
approach
(%)
TA
approach
(%)
Other
approaches
(%)
51 0 646 NR NR NR
6 339 0 167 (49.2) 172 (50.8) 0
34 1038 0 463 (44.6) 575 (55.4) 0
22 109 588 644 (92.4) 26 (3.7) 27 (3.9)
16 166 78 161 (70.0) 71 (29.1) 12 (4.9)
15 187 141 232 (70.8) 88 (26.8) 8 (2.4)
14 0 663 599 (90.3) 0 64 (9.7)
9 130 0 61 (46.9) 69 (53.1) 0
25 410 452 599 (68.9) 271 (31.1)
10 0 118 113 (95.8) 0 5 (4.2)
34 2107 1043 2361 (73.9) 567 (17.7) 267 (8.4)
21 179 0 179 (100) 0 0
25 348 0 244 (70.1) 104 (29.9) 0
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Fig. 1 e Procedural success across various registries.
Although procedural success was not formally defined in
the PARTNER trial, the transcatheter closure was either
aborted or could not be performed in 4.6% and 3.4% of
patients in cohort A and cohort B respectively.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1402PARTNER trial reported outcomes with the Edwards
balloon expandable valve in two different cohorts: Cohort A
comprised of high-risk patients with AS who were random-
ized to TAVR or SAVR9,11; cohort B comprised of inoperable AS
patients who were randomized to TAVR or standard therapy
including balloon aortic valvuloplasty.8,10
Table 2demonstrates thebaseline characteristicsofpatients
included in individual multicenter registries and the PARTNER
trial cohorts. The mean age in all registries was consistently
greater than 80 years and the proportion of males varied from
44.0e59.3%. There was a significant heterogeneity in the risk
profile of patients in various registries. The lowest risk profile
was reported in theAustralianNewZealand registry reportinga
mean (SD) logistic EuroSCORE of 18.4 (11.9)%.17 In addition to
this registry, the UK-TAVI registry also had similar risk profile
patients with a median (IQR) logistic EuroSCORE of 18.5
(11.7e27.9)%.18 On the contrary, the other registries had mean
logistic EuroSCORE > 20%. The highest risk patients were re-
ported in the PARTNER-EU registry with mean (SD) logistic
EuroSCORE of 30.0 (13.7%).16 Themean (SD) logistic EuroSCORE
in the PARTNER cohort A and cohort B patients undergoing
TAVRwas29.3 (16.5)and26.4 (17.2), respectively.8,9Withthedue
consideration of the logistic EuroSCORE in the decisionmaking
for TAVR, it is important to remember that a large proportion of
patients are refused for SAVRandundergoTAVRon thebasis of
risk factors such as frailty or porcelain aorta, neither of which
are a part of traditional surgical risk calculators.3. Procedural success
The procedural success in the representative registries has var-
ied from 88.5e98.4% [Fig. 1]. Although procedural success wasTable 2 e Preoperative characteristics of included patients in v
Registry/n Mean (SD)
age
(years)
%
males
Mean (SD)
logistic
EuroSCORE,
%
Mean (SD)
STS
score, %
Registry data
European
registry/646
81.0 (6.6) 46.1 23.1 (13.8) e
Canadian/339 81.0 (8.0) 44.8 e 9.8 (6.4)
SOURCE/1038 81.1 (6.9) 44.6 27.6 (15.6) e
German/697 81.4 (6.3) 44.2 20.5 (13.2) e
FRANCE/244 82.3 (7.3) 56.6 25.6 (11.4) 18.9 (12.8)
Belgian/328 83.0 (6.0) 54.0 28.0 (16.0) e
Italian/663 81.0 (7.3) 44.0 23.0 (13.7) e
PARTNER-
EU/130
82.1 (5.5) 44.6 30.0 (13.7) 11.6 (6.5)
UK-TAVI/870 81.9 (7.1) 52.4 18.5 (11.7e27.9)a e
Australia New
Zealand/118
82.3 (7.7) 59.3 18.4 (11.9) 5.6 (2.7)
FRANCE 2/3195 82.7 (7.2) 51.0 21.9 (14.3) 14.4 (11.9)
Randomized control trial data
PARTNER B/179 83.1 (8.6) 45.8 26.4 (17.2) 11.2 (5.8)
PARTNER A/348 83.6 (6.8) 57.8 29.3 (16.5) 11.8 (3.3)
AVA: aortic valve area.
a Median (interquartile range).not formally defined in the PARTNER trial, the transcatheter
closurewaseitherabortedor couldnotbeperformed in4.6%and
3.4%ofpatients incohortAandB, respectively. Thereareseveral
reasons for a wide range for procedural success across various
registries. Firstly, there was a difference in the definition of
“Procedural Success” across the various registries. Secondly, the
registries represent the different time periods in the develop-
ment of TAVR technology. In addition, the learning curve phe-
nomenonmighthavesomenegative influenceontheprocedural
success rates. Most of the contemporary registries describearious registries and clinical trials.
%
CAD
%
Stroke
% NYHA
class
III/IV
Mean (SD)
AVA (cm2)
Mean (SD)
gradient,
mmHg
Mean
(SD) LVEF,
%
56.8 7.4 82.4 0.6 (0.2) 49.4 (13.9) 51.5 (13.9)
69.0 22.7 90.9 0.6 (0.2) 46.0 (17.0) 55.0 (14.0)
51.9 e e e e e
60.5 8.2 87.2 0.6 (0.2) 47.0 (37e60)a 52.1 (15.0)
41.3 10.2 74.5 0.7 (0.2) 46.0 (16.0) 51.0 (14.0)
58.0 15.0 79.0 0.6 (0.2) 49.0 (16.0) 55.0 (14.0)
48.3 7.2 65.5 0.6 (0.2) 51.8 (17.0) 52.1 (25.5)
60.0 e 84.6 0.6 (0.2) 47.3 (18.9) 52.8 (16.1)
47.6 e 77.0 e e e
e e 83.9 0.7 (0.2) 50.6 (16.2) 57.8 (13.0)
47.9 10.0 75.9 0.7 (0.2) 48.1 (16.5) 53.2 (14.1)
67.6 27.4 92.2 0.6 (0.2) 44.5 (15.7) 53.9 (13.1)
74.9 29.3 94.3 0.7 (0.2) 42.7 (14.6) 52.5 (13.5)
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1 403pooled outcomes from all the aspects of the learning phase
including patient selection and imaging as well as procedural
expertiseanddevelopmentofbailout strategies.However, in the
more recent experience with the new valve types and delivery
systems, the procedural success rates as well as the efficacy
rates have improved and we can expect even better procedural
outcomes in the coming years.4. Mortality
The pooled incidence of all-cause mortality and cardiovascu-
lar related mortality across various multicenter registries and
the PARTNER cohorts is demonstrated in Fig. 2. The pooled 30-
day all-cause mortality rate (95% CI) in the multicenter regis-
tries was estimated as 9.2 (7.8e10.5)%. On the other hand, the
pooled 30-day all-cause mortality rate in the PARTNER trial
cohorts was estimated to be significantly lower [3.8
(2.2e5.5)%]. Several factors may have contributed to the lower
30-day mortality rates in the PARTNER trial. All patients that
were enrolled in the PARTNER trial underwent a rigorous pre-
procedural assessment and an extensive procedural planning
in order to avoid any unforeseen complications. The trial sites
included the best valve centers with very good infrastructure
for the procedure. Finally, there might be societal and cultural
differences in how complications were managed in this very
elderly population in the US compared to outside US.
Despite the differences in 30-day mortality rates observed
between the multicenter registries and the PARTNER cohorts,
the pooled 1-year all-cause mortality rates were similar be-
tween the two groups [Fig. 3]. This highlights the fact that
procedural mortality is important but the patient selection is
probably more important in these patients because there is a
considerable risk of mortality in the first year even after the
successfulprocedure.Thepooledone-yearmortality rates (95%
CI) in themulticenter registries and the PARTNER trial cohorts
was estimated as 22.9 (19.0e26.9)% and 26.9 (20.7e33.2)%,
respectively. Only two registries havepublished data for follow
up longer than one year.20,23 The two-year mortality rate wasFig. 2 e 30-day (panel A) and 1-year (panel B) all-cause mortalitobserved to be 26.3% and 30.3% in the UK-TAVI and the Italian
registries, respectively.18,22 The 3-year mortality rate has been
reported to be 34.8% in the Italian registry.24 The 2-year mor-
tality rates in the PARTNER cohort A and cohort B have been
observed to be 33.9% and 43.3%, respectively.10,11
The distribution of cardiovascular related deaths is
particularly interesting (Fig. 3). A large majority of all deaths
occurring within 30 days period after TAVR are procedure
related cardiovascular deaths. However, this proportion of
majority shifts rather quickly. At one-year follow up, a sig-
nificant proportion of all deaths happened due to non-
cardiovascular causes. The pooled 30-day cardiovascular
mortality rate (95% CI) in the multicenter registry and the
PARTNER trial cohorts was estimated as 7.0 (5.9e8.1)% and 3.6
(2.0e5.1)%, respectively. At one-year, cardiovascular mortality
rate (95% CI) was estimated to be 13.4 (9.6e17.2)% and 16.5
(11.4e21.6)% in the registry and the trial arm, respectively.
In the FRANCE 2 registry, the incidence of all-cause mor-
tality and non-cardiovascular mortality at one year were re-
ported to be 24.0% and 9.7%, respectively.15 Similarly, in the
Belgian registry, about 65% of all deaths at one-year follow up
were attributable to non-cardiovascular causes.19 The results
are equally striking at the two-year and three-year follow up
reported in the Italian registry.24 Roughly 60% of the all deaths
occurring at two-year and three-year follow-up intervals were
attributable to non-cardiovascular causes.24 Most of these
patients die as a result of co-morbidities or secondary to
conditions associated with advanced age. One could argue,
that since a significant proportion of patients die due to non-
cardiovascular causes, almost half of these patients should be
denied TAVR in accordance with the 2008 European position
statement on TAVR, which stated that this procedure should
not be performed on patients with a life-expectancy < 1
year.25 In the future, it would be crucial to identify patient
population that is likely to derive the most advantage from
application of TAVR technology, in the perspective of cost-
effectiveness. In an analysis performed by Ussia et al, it was
suggested that although there was no significant difference in
cardiovascular mortality between the moderate risk and they across multicenter registries and PARTNER trial cohorts.
Fig. 3 e 30-day (panel A) and 1-year (panel B) cardiovascular related mortality across multicenter registries and PARTNER
trial cohorts.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1404high-risk cohorts, there was a significant difference in the
non-cardiovascular mortality in the high-risk population.24
This would indirectly suggest that application of TAVR tech-
nology to lower-risk groups might demonstrate improved
cardiovascular survival and quality of life with an added
advantage of a lower non-cardiovascular related mortality.5. Stroke
The pooled 30-day and 1-year stroke rate obtained from
multicenter registries was estimated to be 2.6 (1.9e3.2)% and
3.8 (2.3e5.3)%, respectively [Fig. 4]. Only a few registries have
reported stroke rates uponmedium-term follow-up.Although,
the incidence rate of major stroke is consistent between
several European registries, there appears to be a discrepancy
in the rates between the registry data and the PARTNER tri-
al.8e11 In the cohort A of the PARTNER trial, there was a higher
rate of neurological events, of which 40% occurred between 1
month and 1 year after the procedure.9 The pooled 30-day andFig. 4 e 30-day (panel A) and 1-year (panel B) stroke acro1-year stroke rates in the PARTNER trial were estimated to be
5.2 (3.3e7.1)% and 7.6 (3.7e11.4)%, respectively. There are
several possible explanations for these discrepant findings.9
Firstly, the prevalence of pre-existing cerebrovascular dis-
ease (w30%) in thePARTNER trial couldplay a role in thehigher
incidence of stroke in the trial as compared to the registry data.
Secondly, the devices used were first generation devices and
that may be responsible for somewhat higher stroke rates.
Thirdly, and most importantly all patients underwent neuro-
logic examination andNIH scoring before the procedure and at
discharge from the hospital by trained personnel. Moreover,
the diagnosis of strokewas adjudicated byCEC in the PARTNER
trial as compared to cardiologists and anesthesiologists
assessing neurological function after TAVR in most registries.
This may result in underestimation of clinically relevant
neurological events in the registry-derived data. Magnetic
resonance imaging (MRI)based studies have demonstrated
cerebral perfusion defects in approximately 70e80% of the
patients undergoing TAVR.26 Although majority of these pa-
tients are asymptomatic from a neurological standpoint, thisss multicenter registries and PARTNER trial cohorts.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1 405highlights the need for a systematic assessment of neurolog-
ical function including cognitive abilities.266. Post-procedure aortic regurgitation
Moderate/severe paravalvular aortic regurgitation (AR) has
been shown to be associated with increased risk of death on
follow-up.15,18 Whether the degree of AR is responsible for an
early mortality or is merely a marker for adverse outcomes, is
not currently clear. Although moderate/severe AR is infre-
quent after TAVR, mild paravalvular AR is encountered quite
commonly. The clinical significance ofmild paravalvular AR is
under intense investigation. Small studies have demonstrated
that there were no adverse effects of mild AR on left ventric-
ular function at medium-term follow-up period.27 On the
contrary, a recently published meta-analysis demonstrated a
trend toward an increased mortality even in patients with
mild paravalvular AR.28 This trend toward increasedmortality
with mild paravalvular AR was also observed in the 2-year
follow up of the PARTER-A trial.11 Echocardiographic follow
up of 2-year survivors in the PARTNER-A trial demonstrated
that the paravalvular AR improved in 42.6%, did not change in
41.0% and worsened in 16.4%. None of the patients in the
TAVR group had AR that worsened to a moderate/severe de-
gree during follow-up. With the adoption of TAVR for lower-
risk, younger individuals, there might be a lower tolerance
toward mild paravalvular AR, requiring revisions in valve
design to ensure flush circumferential annular apposition.
Table 3 demonstrates the incidence of post-procedure AR
upon short-term and medium-term follow-up. The pooledTable 3 e Post procedure aortic regurgitation (grade 2 or
higher) after transcatheter aortic valve replacement.
Registry/n/year 30-day follow up,
% incidence
Long-term
follow up,
% incidence
Registry data
Canadian/339/2010 6.0 e
SOURCE/1038/2010 1.9a e
German/697/2010 17.6 e
FRANCE/244/2010 9.5 e
UK-TAVI/870 13.6 e
Italian/663/2011 20.1 1 year: 17.8
2 year: 16.5
3 year: 10.1
PARTNER-EU/130/2011 47.0 1 year: 25.0
UK-TAVI/870/2011 13.6 e
FRANCE 2/3195/2012 18.7 6 months: 18.7
1 year: 20.3
POOLED ESTIMATE
(95% CI)
20.6 (13.4e27.8) 1 year: 19.9
(17.4e22.4)
Randomized control trial data
PARTNER B/179/2010 20.0 1 year: 15.0
2 year: 9.0
PARTNER A/348/2012 13.1 1 year:
7.12 year: 6.9
POOLED ESTIMATE (95% CI) 16.1 (9.4e22.9) 1 year: 7.5
(5.3e9.8)
a AR grade 3 þ or higher.incidence (95% CI) of moderate or severe AR at 30 days after
TAVR has been estimated to be 20.6 (13.4e27.8)% and 16.1
(9.4e22.9)% across themulticenter registries and the PARTNER
trial cohorts, respectively. At 1-year followup, the incidence of
moderate or severe AR was estimated to be 19.9 (17.4e22.4)%
and 7.5 (5.3e9.8)% across the multicenter registries and the
PARTNER trial cohorts, respectively. The 2-year and 3-year
follow up AR rates were reported to be 16.5% and 10.1% in
the Italian CoreValve registry.247. Arrhythmias, conduction abnormalities
and pacemaker implantation
Arrhythmias and conduction abnormalities are important
concerns after TAVR. Although supraventricular and ventric-
ular arrhythmias have been observed after TAVR at varying
frequencies, they are encountered in roughly 20e30% of pa-
tients after SAVR and any valid comparison of frequency of
arrhythmias between the two strategies would need to
include a careful analysis of post-therapy arrhythmias.29 The
occurrence of new onset left bundle branch block after SAVR
has been associated with an increased risk of death and sub-
sequent life-threatening arrhythmias during follow up.30,31
New onset intraventricular conduction abnormalities, partic-
ularly the new onset left bundle branch block are encountered
frequently after TAVR (7e18% after Edwards valve implanta-
tion; 30e83% after CoreValve implantation).23,29,32e35 Direct
mechanical injury of the left bundle branch and the inflam-
mation due to the stent prosthesis are likely offenders to the
conduction system. However, the implications of a new onset
left bundle branch block after TAVR upon long-term adverse
outcomes are not well understood.
In several instances, the conduction system abnormalities
arising as a result of prosthetic valve placement necessitate the
implantation of permanent pacemaker. Fig. 5 demonstrates the
incidence of permanent pacemaker implantation in the
Edwards valve and CoreValve cohorts. At 30-day follow-up
period, the pooled incidence of permanent pacemaker im-
plantation in the Edwards valve cohort and the CoreValve
cohort in the multicenter registries was observed to be 7.6
(4.0e11.3)% and 25.7 (16.7e34.7)%, respectively. Among the
Edwards valve cohorts, all registries except the German registry
reported 30-day pacemaker implantation rate less than 10%.20
On the other hand, among the CoreValve cohorts, all regis-
tries except the multicenter expanded evaluation registry and
the Italian registry reported pacemaker implantation rate
greater than 20%. Among the Edwards valve cohorts, the 1-year
pacemaker implantation rate was reported to be 3.1% in the
PARTNER-EU registry and 11.5% in the FRANCE 2 registry.15,16
Among the CoreValve cohorts, the 1-year pacemaker implan-
tation rate was reported to be 19.1% in the Italian registry and
24.2% in the FRANCE 2 registry.15,22 The pooled incidence (95%
CI) among the PARTNER cohorts, which utilized the Edwards
balloon expandable valves, was calculated to be 3.7 (2.1e5.3)%.
Among procedural variables, the use of CoreValve system
and the deeper (ventricular) implantation of the valve pros-
thesis have been identified as the most important variables
predicting the need for permanent pacemaker implantation.36
The nitinol frame of the CoreValve system exerts a higher
..
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Fig. 5 e 30-day permanent pacemaker implantation rates across the multicenter registries and PARTNER trial cohorts.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1406radial strength on the ventricular septum as compared to the
stainless steel or cobalt chromium frame of the Edwards
valve, leading to an increased risk of damage to the conduc-
tion system. Further, the length of the device also adds to the
forces on the conduction system due to torsional motion of
the aortic root and the angle between the left ventricular
outflow and the ascending aorta. The impact of permanent
pacemaker implantation on long-term outcomes has been
poorly explored in patients undergoing TAVR.8. Vascular complications and other adverse
events after TAVR
Table 4 demonstrates the vascular complications and
bleeding events that may arise after TAVR. There is a signifi-
cant heterogeneity in the definition and classification of
bleeding and vascular complications. The VARC recommends
classification of bleeding events as life-threatening,major and
minor bleeding events.37 The life-threatening and major
bleeding event rates have ranged between 3.2% in the Italian
CoreValve registry and 8.5% in the PARTNER-EU registry.16,22
The incidence of major and minor vascular complications
has ranged between 1.9e13.3% and 4.6e10.4%, respectively,
across the various registries. The incidence of major vascular
complications in the PARTNER cohort A and cohort B was
11.0% and 16.2%, respectively.8,9 The impact of vascular
complication onmortality was more pronounced in the initial
reports; but with increasing awareness, smaller devices and
better bailout strategies, the impact of vascular complication
on mortality is lower but in no ways insignificant.9. Myocardial infarction
The incidence of MI at 30 days has ranged from 0 to 4.6%
across the registries. The one-year incidence of MI in the
multicenter registries has been observed to be between 1.2
and 6.2%. The variability in the MI rates stems from the lack
of uniformity in the definition of periprocedural MI among
the various TAVR registries. The pooled incidence (95% CI) of
30-day MI in the multicenter registries and the PARTNER
trial was calculated to be 0.6 (0.2e1.1)% and 0 (0e0.4)%
respectively. Similarly, the pooled incidence (95% CI) of one-
year MI in the multicenter registries and the PARTNER trial
was calculated to be 1.7 (0.3e3.0)% and 0.5 (0e1.0)%,
respectively.10. Edwards valve versus CoreValve
Most of the contemporary data is derived from centers that do
not perform both CoreValve and Edwards valve procedures,
which is a significant limitation in drawing inferences about
the comparison of two strategies. It must be noted that valve-
to-valve comparisons are available only from the registries
whereas TAVR versus SAVR comparisons are available only
from the PARTNER trial. Until the introduction of the Sapien
XT valve and low profile delivery systems by Edwards, Cor-
eValve had the advantage of smaller delivery catheter system
(18 Fr) for the transfemoral access. In a few centers that
implant both types of valves, valve selection has been related
to annulus sizing, femoral artery access and availability of
newer delivery systems. The CoreValve is available in a 31mm
Table 4 e Bleeding and vascular complications after transcatheter aortic valve replacement across various registries and
randomized trials.
Registry/n/year Bleeding, % incidence Vascular complications, % incidence
Life-threatening Major Minor Major Minor
Registry data
European registry/646/2008 e e e 5.6a
Canadian/339/2010 e e e 13.3 e
SOURCE/1038/2010 e e e 10.6 10.4
German/697/2010 19.5b
FRANCE/244/2010 21.3 7.3
Italian/663/2011 3.2 e 3.2c
PARTNER-EU/130/2011 8.5 12.3 10.8 5.4
UK-TAVI/870/2011 e e e 6.3 e
Australia New Zealand/118/2011 e e e 1.9 4.3
FRANCE 2/3195/2012 1.2 4.5 7.4 4.7 5.0
Randomized control study data
PARTNER B/179/2010 16.8 e 16.2 14.5
PARTNER A/348/2011 9.3 e 11.0 6.0
a Includes aortic root dissection/perforation, ventricular perforation, cardiac tamponade and access site complications.
b Indicated as “Groin problems”.
c Includes major access site complications and cardiac tamponade.
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Edwards valve. On the other hand, the Edwards valve has an
advantage of a lower incidence of conduction abnormalities
and need for permanent pacemaker implantation post-
procedurally.Table 5 e Incidence of death, myocardial infarction and stroke
replacement stratified by valve type.
Registry/n/year All-cause mortality, % incidence Myoc
30 days Follow up 30
Edwards valve
Canadian/339/2010 10.6 8 months: 22.1
SOURCE/1038/2010 8.5 e
FRANCE/166/2010 12.0 e
Belgian/187/2010 11.8 1 year: 27.2
PARTNER-EU/130/2011 13.8 6 months: 26.9
1 year: 36.9
UK-TAVI/410/2011 8.5 1 year: 20.6
2 year: 28.3
FRANCE 2/2107/2012 9.6 6 months: 18.1
1 year: 24.0
CoreValve
European registry/
646/2008
8.0 e
FRANCE/78/2010 14.1 e
Belgian/141/2010 10.6 1 year: 21.3
Italian/663/2011 5.9 1 year: 14.9
2 year: 30.3
3 year: 34.8
UK-TAVI/452/2011 5.8 1 year: 21.7
2 year: 23.9
Australia New
Zealand/118/2011
5.6 10.5
FRANCE 2/1043/2012 9.4 6 months: 19.6
1 year: 23.7
a Only procedural rates available. 30-day event rate was not available.Table 5 demonstrates the incidence rates of death, MI and
stroke in patients undergoing TAVR stratified by the valve
type. Among the Edwards valve cohorts, the 30-day incidence
of death, MI and stroke ranged between 8.5 and 13.8%,
1.2e4.6% and 2.3e5.2%, respectively. Among the CoreValvein patients undergoing transcatheter aortic valve
ardial infarction, % incidence Stroke, % incidence
days Follow up 30 days Follow up
1.2 e 2.3 e
e e 2.6 e
e e 3.6 e
e e Stroke: 5.0
TIA: 1.1
e
4.6 6 months: 6.2
1 year: 6.2
2.3 6 months: 5.4
1 year: 6.9
1.5 e 4.2 e
e 1 year: 0.8 e 1 year: major (1.9)
minor (1.9)
0.6 e 1.9 e
e e 3.8 e
e e Stroke: 3.6
TIA: 0.7
e
0a 1 year: 1.2
3 year: 1.2
1.2a 1 year: 2.6
3 year: 3.9
1.1 e 4.0 e
e e 1.7 e
e 1 year: 1.9 e 1 year: major (2.6)
minor (1.7)
Table 6 e Comparison of mortality and stroke rates across various registries and randomized trials stratified by transapical (TA) and transfemoral (TF) approaches.
Study (TA/TF n)/
year
Transapical TAVR Transfemoral TAVR
Mean (SD)
EuroSCORE, %
30-day death,
%
30-day
stroke, %
Long-term death, % Long-term
stroke, %
Mean (SD)
EuroSCORE, %
30-day
death, %
30-day
stroke, %
Long-term
death, %
Long-term
stroke, %
Registry data
Canadian
(177/162)/2010
ea 11.3 1.7 8 mo: 19.8 e ea 9.5 3.0 8 mo: 24.7 e
SOURCE
(575/463)/2010
29.1 (16.3) 10.3 2.6 e e 25.7 (14.5) 6.3 2.4 e e
FRANCE
(71/161)/2010
26.8 (11.6) 16.9 2.8 e e 25.2 (11.2) 11.1 4.3 e e
Belgian
(88/99)/2010
33.0 (17.0) 14.0 8.2 6 mo: 29.0
1 year: 37.0
e 29.0 (15.0) 6.0 2.1 6 mo: 9.0
1 year: 18.0
e
PARTNER-EU
(69/61)/2011
33.8 (14.4) 18.8 1.4 6 mo: 42.0
1 year: 50.7
6 mo: 5.8
1 year: 7.2
25.7 (11.5) 8.2 3.3 6 mo: 9.8
1 year: 21.3
6 mo: 4.9
1 year: 6.6
UK-TAVI
(271b/599)/2011
21.4 (14.4e33.6)c 10.7 4.1 1 year: 27.7
2 year: 36.7
e 17.1 (11.0e25.5)c 5.5 4.0 1 year: 18.5
2 year: 22.5
e
FRANCE 2
(567/2361)/2012
24.8 (14.7) 13.9 e 6 mo: 22.4
1 year: 32.3
1 year: 4.4 21.2 (14.7) e 6 mo: 17.2
1 year: 21.7
1 year: 3.8
POOLED ESTIMATE
(95% CI)
12.2 (10.4e14.1) 2.7 (1. e3.9) 1 year: 32.2 (24.7e39.7) 1 year: 4.6
(3.0e6.2)
6.8 (5.3e8.4) 3.1 (2.2e4.0) 1 year: 20.8
(18.9e22.8)
1 year: 3.8
(3.1e4.6)
Randomized clinical trial data
PARTNER A
(104/244)
29.8 (15.9) 3.8 6.8 1 year: 29.0
2 year: 41.1
1 year: 9.3
2 year: 12.5
29.1 (16.1) 3.3 3.7 1 year: 22.2
2 year: 30.9
1 year: 4.6
2 year: 5.9
PARTNER B (0/179) e e e e e 26.4 (17.2) 5.0 6.7 1 year: 30.7
2 year: 43.3
1 year: 10.0
2 year: 13.8
POOLED ESTIMATE
(95% CI)
3.8 (1.4e6.2) 6.8
(3.6e10.0)
1 year: 29.0
(23.3e34.7)
1 year: 9.3
(5.7e12.9)
3.9 (2.1e5.7) 4.9 (2.0e7.7) 1 year: 26.2
(17.9e34.5)
1 year: 7.0
(1.7e12.3)
a Mean logistic EuroSCORE was not reported in this registry. Mean (SD) STS scores in the transapical cohort were 10.5 (6.9) % and 9.0 (5.8)% in the transapical and transfemoral TAVR cohorts
respectively ( p ¼ 0.034).
b Transapical TAVR outcomes not reported separately. The outcomes for “Other routes” were compared with those after transfemoral TAVR.
c Median (interquartile range).
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between 5.6 and 14.1%, 0e1.1% and 1.2e4.0%, respectively.
The distribution of long-term all-cause mortality also appears
to be similar between the two valve types across the available
registries (Table 5).11. Transfemoral versus non-transfemoral
approaches
Table 6 demonstrates the incidence rates of all-cause mor-
tality and stroke in the patients undergoing transfemoral and
transapical TAVR. In the transfemoral cohorts of the multi-
center registries, the pooled 30-day and 1-year mortality rates
were observed to be 6.8 (5.3e8.4)% and 20.8 (18.9e22.8)%,
respectively. In the transapical cohorts of the multicenter
registries, the pooled 30-day and 1-year mortality rates were
observed to be 12.2 (10.4e14.1)% and 32.2 (24.7e39.7)%,
respectively. Among the PARTNER trial cohorts, the pooled
incidence of 30-day and 1-year mortality rates were 3.9% and
26.2% in the transfemoral TAVR group and 3.8% and 29.0% in
the transapical TAVR group. Several registries have reported
significantly higher all-cause mortality among patients un-
dergoing transapical TAVR as compared to those undergoing
transfemoral TAVR.19,24,25 The difference is likely secondary to
the higher risk profile of the patients undergoing transapical
TAVR as compared to the patients undergoing transfemoral
TAVR. As is clearly evident in Table 6, the logistic EuroSCORE
in the transapical TAVR was consistently higher than that in
the transfemoral cohort. Although inadequate peripheral
vascular access is the most common reason for transapical
approach, the transapical patients are higher risk individuals
because of a systematic selection bias that has occurred with
the delivery approach, especially across the multicenter reg-
istries. The selection bias results in a significantly higher
prevalence of comorbidities in the transapical cohort; thereby,
resulting in a higher short-term and medium-term mortality.12. Long-term follow up studies
Surgically implanted aortic bioprostheses have shown 10-year
freedom from prosthetic failure in the range of 60e90%, with
younger patients predisposed toward premature deteriora-
tion.38,39 At 5 years, freedom from structural valve failure is
generally greater than 95%. Although premature failure
requiring repeat operation or leading to adverse clinical con-
sequences has been described, freedom from repeat operation
at 5 years is also generally greater than 95%.38,39 Whether
TAVR can achieve similar outcomes remains to be seen.
The data on long-term results following TAVR are rather
scarce. Gurvitch et al reported a survival rate of 51% at 3-year
follow-up in a cohort of 88 patients, who had undergoing
TAVR with the Edwards valve in 2005e2006.40 After discount-
ing the patients who died within the first 30 days, the survival
rateswere 74%and61%at 2-year and 3-year follow-upperiods,
respectively.40 Besides this, the incidence of MI, stroke and
pacemaker implantationat3-year followupwas8.6%,8.6%and
7.1%, respectively. In the surviving patientswhowere inNYHA
Class 3 and 4 at baseline, 85% and 100% of patients hadimproved by at least one functional class, respectively. The
study demonstrated good valve durability, with no evidence of
structural deterioration or need for reoperation at the median
followupof3.7years. Long-termfollow-upresultsof the Italian
CoreValve registry demonstrated a sustained clinical and
functional cardiovascular benefit among patients undergoing
TAVR with 18 Fr CoreValve up to a 3-year follow-up period.24
Despite these preliminary data on long-term follow-up after
TAVR, lack of large head-to-head comparisons between treat-
ment strategies for AS (including TAVR) precludes definitive
conclusions about long-term clinical outcomes.13. Conclusions
The evidence derived from multicenter registries and the
randomized trials has provided several unique insights. The
data from the available multicenter registries have clearly
demonstrated that patient selection would be the key to cost-
effective utilization of this revolutionary technology. The
strength of data from the multicenter registries includes
applicability to a large variety of patient population undergo-
ing procedures in real-world settings across the world. On the
other hand, the clinical trials help establish benchmarks for
safety and efficacy related data, against which the real-world
experiences may be compared. As seen in our review, the
short-term results reported in the randomized trial appear to
be better compared to those reported in the multicenter reg-
istries. This may be because of better patient selection, expert
centers and more aggressive bailout techniques, which may
have improved short-term results. Although the patient pop-
ulation was sicker in the PARTNER trial evidenced by a higher
logistic EuroSCORE, the characterization of patients in the
registries is less stringent.
Although the PARTNER trial has provided thorough com-
parison of TAVR versus SAVR, it fails to provide the data
regarding comparisons of available devices. These compari-
sons can be sought only from the experiences reported as a
part of large multicenter registries. Both the Edwards valve
and the CoreValve have demonstrated in improving symp-
toms and survival after TAVR in patientswith severe AS. Other
than the greater need for permanent pacemaker in patients
undergoing CoreValve implantation, other outcomes for these
devices have been comparable with minor differences. The
comparison of transfemoral versus transapical approaches for
TAVR has demonstrated superior outcomes for the former
approach. However, the profile of patients undergoing trans-
apical TAVR is significantly different with significantly greater
comorbidities and a higher logistic EuroSCORE as compared to
patients undergoing transfemoral TAVR.
One of the important differences between the outcomes of
the PARTNER trial and the multicenter registries includes a
significantly higher rate of stroke reported in the PARTNER trial.
This could be attributed to a higher prevalence of pre-existing
cerebrovascular disease in the PARTNER population. Moreover,
the diagnosis of stroke was adjudicated by CEC in the PARTNER
trial as compared to cardiologists and anesthesiologists assess-
ing neurological function after TAVR in most registries. This
might have resulted in underestimation of clinically relevant
neurological events in the registry-derived data.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 4 0 0e4 1 1410The impact of co-morbid conditions like frailty, respiratory
failure, pulmonaryhypertensionandseveremitral regurgitation
on long-term outcomes following TAVR need to be definitively
established. As the experience in TAVR implantation grows and
the device design continues to improve in the coming years, one
would hope that the technology would become available to
lower-risk AS patients with equivalent or superior outcomes
compared to conventional SAVR. At this time, off label use of
TAVR should be vigorously avoided, given the good and pre-
dictable results of SAVR as well as the lack of robust long-term
data about durability of TAVR. As the improvement of TAVR
technology continues, registry data would be paramount in
order to maintain and monitor efficacy and safety related out-
comes in patients undergoing TAVR across the world.Conflicts of interest
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